Long-Term Safety and Efficacy of Dazukibart in Dermatomyositis: Combined Phase II Results From Double-Blind and Open-Label Extension Studies.
Ruth Ann Vleugels, Elena Peeva, Rohit Aggarwal et al.
✦ AI-curated · Sources linked
In 30 seconds
This study evaluated the long-term safety and efficacy of dazukibart, an antiinterferon β monoclonal antibody, in adults with moderate-to-severe dermatomyositis through a combined Phase II randomized controlled trial and open-label extension. The results showed that treatment-emergent adverse events were predominantly mild (55%), and significant improvements in CDASI-A scores were observed, with a median change of -24.0 in the skin-predominant cohort at week 76.
Key findings
- 55% of treatment-emergent adverse events were mild, with no serious adverse events reported.
- Median CDASI-A score change was -24.0 in the skin-predominant cohort at week 76.
- Total Improvement Score in the muscle-predominant cohort improved with a median of 65.0 at week 76.
- Improvements in outcomes persisted during the 16-week post-treatment follow-up.
Why it matters
The findings suggest that dazukibart may provide a safe and effective treatment option for patients with dermatomyositis, a condition with limited treatment options. Sustained improvements in disease activity scores could enhance patient quality of life.